Kyriakopoulos CE, et al. - Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. In the Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) trial with more mature follow-up and focus on tumor volume, it was confirmed that the chemohormonal therapy affords clinical benefit in terms of prolonging overall survival (OS) in patients with high-volume disease; however, no OS benefit was noted for patients with low-volume disease.